Stock Screener App

Frei - Play StoreApp Store

Installieren Installieren

Dow:

Nasdaq:

S&P 500:

RARE

$16.104.05%-0.68

Vorbörslich: 16.12+0.02 +0.12%

Ultragenyx Pharmaceutical Inc (RARE)

Date: O: H: L: C: Vol:

Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten

Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out for - Zacks Investment Research

GSK (GSK) Q3 Earnings and Revenues Beat Estimates - Zacks Investment Research

Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release - Zacks Investment Research

Form DEF 14A Ultragenyx Pharmaceutical Inc For: 21 October By Investing.com - Investing.com Australia

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Has Consensus Price Target of $33.65 According to Brokerages - MarketBeat

Ultragenyx Pharmaceutical Inc. $RARE Stock Acquired by Assenagon Asset Management S.A. - MarketBeat

Six parties report the same passive stake above 5% in Ultragenyx (RARE). - Stock Titan

Form 4 Ultragenyx Pharmaceutical Inc: Howard Horn (CFO) For: 15 October - Investing.com Nigeria

Ultragenyx CFO Howard Horn sells $107,897 in company stock - Investing.com

Ultragenyx Pharmaceutical Enters Settlement With Navinta Over Dojolvi - marketscreener.com

Ultragenyx Pharmaceutical Enters Settlement With Navinta Over Dojolvi - Yahoo Finance

Ultragenyx to allow generic DOJOLVI launch from Jan 1, 2033 under settlement - TradingView

Ultragenyx Pharmaceutical Inc. (RARE.MX) Analyst insights, Price targets and Recommendations - Yahoo Finance UK

Ultragenyx Pharmaceutical Inc. (RARE) Options Chain - Yahoo! Finance Canada

Ultragenyx Pharma Initiated at Neutral by UBS - Moomoo

Ultragenyx In The Money As PRV Income Tops $400m - Scrip

RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week - Zacks Investment Research

Ultragenyx Rare Disease Voucher Sales Secure $413M for More Potential Pipeline Building - MedCity News

Can RARE's Approved Product Portfolio Drive Its Next Growth Phase? - Zacks Investment Research

Funds from operations of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE - TradingView

Analysts Have Conflicting Sentiments on These Healthcare Companies: Verastem (VSTM), Ultragenyx Pharmaceutical (RARE) and UnitedHealth (UNH) - The Globe and Mail

Ultragenyx Sells Rare Pediatric Disease Priority Review Voucher | PharmExec - Pharmaceutical Executive

Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million - Pharmaceutical Executive

Ultragenyx cashes in Genglycos-derived priority review voucher for $210M - FirstWord Pharma

Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash - Zacks Investment Research

Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash - Yahoo Finance

Ultragenyx to sell rare PRV for $210 million - The Pharma Letter

Is Ultragenyx Pharmaceutical (RARE) Undervalued Following EMA Validation For Its Sanfilippo Gene Therapy? - Yahoo Finance

Form PRE 14A Ultragenyx Pharmaceutical Inc For: 7 October By Investing.com - Investing.com Nigeria

Ultragenyx Pharmaceutical agrees to sell rare pediatric voucher for US$210M - Mugglehead Investment Magazine

Ultragenyx sells PRV for $210M and still has another voucher it plans to monetize - Endpoints News

Ultragenyx shares rise 3.2% after selling FDA p... - Pluang

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Jumps 3.9% - Here's Why - MarketBeat

Ultragenyx Lands $210M Deal To Sell FDA Priority Review Voucher – Retail Sees ‘Huge’ Buying Opportunity - TradingView

Ultragenyx (RARE) Stock Rises on $210M Priority Review Voucher S - GuruFocus

Ultragenyx to sell FDA priority review voucher for $210M (RARE) - Seeking Alpha

Ultragenyx to sell rare disease priority review voucher for $210m - Investing.com

Ultragenyx (RARE) Sells Rare Pediatric Disease Priority Review V - GuruFocus

Ultragenyx Pharmaceutical - Under Deal With U.S. Department Of Health Co To Pay 20% Of Prv Sale Proceeds To Nih - TradingView

Ultragenyx to Sell Priority Review Voucher for $210 Million; 20% Payable to NIH - TradingView

A voucher that can speed FDA review is set to sell for $210 million. - Stock Titan

Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million - GlobeNewswire

Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million - Proactive financial news

Ultragenyx (RARE) EMA Validation of MPS IIIA Gene Therapy: Inflection Point or Incremental Milestone? - Yahoo Finance

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of OSI Systems, Inc. - OSIS - GlobeNewswire Inc.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE - GlobeNewswire Inc.

Ultragenyx Pharmaceutical Inc. (RARE) stock price, news, quote and history - Yahoo Finance UK

Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Down 6% - Here's Why - MarketBeat

Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation - Yahoo Finance

Ultragenyx Pharmaceutical Inc. (RARE) Stock Price, News, Quote & History - Yahoo! Finance Canada

Ähnlich wie RARE

NBTX$31.377.19%

URGN$32.722.27%

IMCR$30.492.49%

MLYS$18.1814.41%

GPCR$21.870.32%

INVA$21.220.42%